| Literature DB >> 31807332 |
Abstract
Benign prostatic hyperplasia (BPH) is a noncancerous growth of the prostate. BPH commonly occurs in elderly men. Lower urinary tract symptoms (LUTS) secondary to BPH (LUTS/BPH) have significant impacts on their health. Saw palmetto (Serenoa repens) extract (SPE) has been evaluated for its effectiveness in improvement of LUTS/BPH at preclinical and clinical levels. Potential mechanisms of actions include anti-androgenic, pro-apoptotic, and anti-inflammatory effects. However, SPE efficacy was inconsistent, at least partly due to a lack of a standardized SPE formula. A hexane extract (free fatty acids, > 80%) provided more consistent results. Free fatty acids (lauric acid) were effective in inhibition of 5α-reductase, and phytosterol (β-sitosterol) reduced prostatic inflammation. Multiple actions derived from different constituents may contribute to SPE efficacy. Evaluation of the clinical relevance of these bioactive components is required for standardization of SPE, thereby enabling consistent efficacy and recommendations for the use in the prevention and treatment of BPH. © The Korean Society of Food Science and Technology 2019.Entities:
Keywords: Benign prostatic hyperplasia; Fatty acids; Phytosterol; Saw palmetto extract; Standardized formula
Year: 2019 PMID: 31807332 PMCID: PMC6859144 DOI: 10.1007/s10068-019-00605-9
Source DB: PubMed Journal: Food Sci Biotechnol ISSN: 1226-7708 Impact factor: 2.391